FLR
43
-3
CCI
52
3
TEL
88
5
IP
62
-2
DHR
61
5
ACN
42
4
GWW
64
6
LYB
39
-7
KMB
37
-3
BA
48
-4
NWS
88
7
M
48
-5
ADBE
49
4
LRCX
64
6
HD
38
3
LOW
61
3
PGR
69
-3
SHW
64
2
GE
65
4
INTU
72
3
FLR
43
-3
CCI
52
3
TEL
88
5
IP
62
-2
DHR
61
5
ACN
42
4
GWW
64
6
LYB
39
-7
KMB
37
-3
BA
48
-4
NWS
88
7
M
48
-5
ADBE
49
4
LRCX
64
6
HD
38
3
LOW
61
3
PGR
69
-3
SHW
64
2
GE
65
4
INTU
72
3
Financhill
Back

CASI Pharmaceuticals 10K Form

Sell
46

CASI
CASI Pharmaceuticals

Last Price:
3.24
Seasonality Move:
-12.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CASI News And Ratings

See the #1 stock for the next 7 days that we like better than CASI

CASI Financial Statistics

Sales & Book Value

Annual Sales: $33.88M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $1.81
Price / Book: 1.81

Profitability

EPS (TTM): -2.03000
Net Income (TTM): $-26.94M
Gross Margin: $20.05M
Return on Equity: -52.29%
Return on Assets: -32.69%

CASI Pharmaceuticals Earnings Forecast

Key CASI Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 28 years for CASI is 59.19%.
  • The Selling, General & Administrative Expenses for CASI have been equal to 123.49% of Gross Profit Margin.
  • The Research & Development expenses have been 29.11% of Revenue.
  • The Interest Expense is 2.30% of Operating Income.
  • The Net Earning history of CASI is -79.51% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

CASI Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CASI
CUSIP: 14757U
Website: casipharmaceuticals.com

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 3.55
Quick Ratio: 2.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 9.62

CASI Technical Analysis vs Fundamental Analysis

Sell
46
CASI Pharmaceuticals (CASI) is a Sell

Is CASI Pharmaceuticals a Buy or a Sell?